"Centro de Pesquisas Clínicas de Natal"

During the past decade, Centro de Estudos e Pesquisas em Moléstias Infecciosas conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 2 clinical trials were completed, i.e. on average, 22.2% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 2 clinical trials were completed. i.e. 28.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centro de Estudos e Pesquisas em Moléstias Infecciosas" #1 sponsor was "Janssen Vaccines & Prevention B.V." with 3 trials, followed by "D'Or Institute for Research and Education" with 2 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored, "Clover Biopharmaceuticals AUS Pty Ltd" with 1 trials sponsored and "Humanigen, Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro de Estudos e Pesquisas em Moléstias Infecciosas" #1 collaborator was "Bill and Melinda Gates Foundation" with 2 trials as a collaborator, "Coalition for Epidemic Preparedness Innovations" with 1 trials as a collaborator, "Instituto Fernandes Figueira" with 1 trials as a collaborator, "International Vaccine Institute" with 1 trials as a collaborator and "University of Oxford" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Centro de Estudos e Pesquisas em Moléstias Infecciosas" are "COVID-19" (2 trials), "COVID-19 Prevention" (2 trials), "Respiratory Syncytial Virus Infections" (2 trials), "Coronavirus Disease 2019 (COVID-19) Pneumonia" (1 trials) and "Covid19" (1 trials). Many other conditions were trialed in "Centro de Estudos e Pesquisas em Moléstias Infecciosas" in a lesser frequency.

Most popular intervention types in "Centro de Estudos e Pesquisas em Moléstias Infecciosas" are "Biological" (7 trials), "Drug" (3 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Ad26.COV2.S" (3 trials), "Placebo" (3 trials), "Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover)" (1 trials), "AstraZeneca/Fiocruz" (1 trials) and "ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centro de Estudos e Pesquisas em Moléstias Infecciosas" are 8 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Centro de Estudos e Pesquisas em Moléstias Infecciosas". 2 are not yet recruiting, undefined are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Centro de Estudos e Pesquisas em Moléstias Infecciosas, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Centro de Estudos e Pesquisas em Moléstias Infecciosas, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".